Human papillomavirus vaccines for the treatment of cervical cancer

Expert Review of Vaccines

Volumn 5, Issue 6, 2006, Pages 783-792

  Sin, Jeong Im ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

CD4+ Treg cells; Cervical cancer; Chemotherapy; CTL; DC; DNA vaccines; Human papillomavirus; Peptide vaccines; Prophylactic vaccines; Radiotherapy; Subunit vaccines; Therapeutic vaccines; Tumor immunity; Viral bacterial vector delivery

Indexed keywords

ALUMINUM HYDROXIDE; ARGINYLALANYLHISTIDYLTYROSYLASPARAGYLISOLEUCYLVALYLTHREONYLPHENYLALANINE; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; DNA VACCINE; FREUND ADJUVANT; HLA A2 ANTIGEN; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; PEPTIDE VACCINE; PROTEIN E6; PROTEIN E7; QUIL A; RECOMBINANT DNA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR; WART VIRUS VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER CONTROL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RECURRENT CANCER; REGULATORY T LYMPHOCYTE; REVIEW; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS STRAIN; WART VIRUS;

CANCER VACCINES; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 33845866069     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.6.783     Document Type: Review

References (109)

1. zur Hausen H, de Villiers EM. Human papilloma viruses. Annu. Rev. Microbiol. 48, 427-447 (1994).
2. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J. Natl. Cancer Inst. 87, 796-802 (1995).
3. Campion MJ. Clinical manifestations and natural history of genital papillomavirus infections. Obstet. Gynecol. Clin. North Am. 14, 363-388 (1987).
4. Syrjanen KJ. Biology of human papillomavirus infections and their role in squamous cell carcinogenesis. Med. Biol. 65, 21-39 (1987).
5. Lorincz AT, Temple GF, Kurman RJ et al. Oncogenic association of specific papillomavirus types with cervical neoplasia. J. Natl. Cancer Inst.. 79, 671-677 (1987).
6. Cullen AP, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasve cervical neoplasia. J. Virol. 65, 606-612 (1991).
7. Munger K, Phelps WC, Bubb V et al. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol.. 63, 4417-4421 (1989).
8. Dyson N, Howley PM, Munger K, Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind the retinoblastoma gene product. Science 243, 934-937 (1989).
9. Scheffner M, Munger K, Bryne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA 88, 5523-5527 (1991).
10. Werness BA, Levine AJ, Howley PM. Association of HPV type 16 and 18 E6 protein with p53. Science 248, 76-79 (1990).
11. Heck DV, Yee CL, Howley PM, Münger K. Efficiency of binding to the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. USA 89, 4442-4446 (1992).
12. Münger K, Werness BA, Dyson N et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8, 4099-4105 (1989).
13. Stoler MH, Rhodes CR, Whitbeck A et al. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol. 23, 117-128 (1992).
14. Casas L, Galvan SC, Ordonez RM et al. Asian-american variants of human papillomavirus type 16 have extensive mutations in the E2 gene and are highly amplified in cervical carcinomas. Int. J. Cancer 83, 449-455 (1999).
15. Stevenson M, Hudson LC, Burns JE et al. Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia. J. Gen. Virol.. 81, 1825-1832 (2000).
16. Olatunbosun O, Deneer H, Pierson R. Human papillomavirus DNA detection in sperm using polymerase chain reaction. Obstet. Gynecol. 97, 357-360 (2001).
17. de Villiers EM, Wagner D, Schneider A et al. Human papillomavirus DNA in women without and with cytological abnormalities: results of a 5-year follow-up study. Gynecol. Oncol. 44, 33-39 (1992).
18. Schiffman MH, Castle P. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J. Natl. Cancer Inst. 95, E2 (2003).
19. Kirnbauer R, Taub J, Greenstone H et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67, 6929-6936 (1993).
20. Kirnbauer R, Booy F, Cheng N et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89, 12180-12184 (1992).
21. Kirnbauer R, Chandrachud LM, O'Neil BW et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219, 37-44 (1996).
22. Harro CD, Pang Y, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93, 284-292 (2001).
23. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651 (2002).
24. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol. 6, 271-278 (2005). • Clinical effectiveness of quadrivalent virus-like particle (VLP) vaccines against infection with human papillomavirus (HPV) types 6, 11, 16 and 18.
25. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247-1255 (2006). • Clinical effectiveness of bivalent VLP vaccines against infection with HPV types 16 and 18.
26. de Gruijl TD, Bontkes HJ, Stukart MJ et al. T cell proliferative responses against 18 human papilomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J. Gen. Virol. 77, 2183-2191 (1996).
27. Petry KU, Scheffel D, Bode U et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int. J. Cancer 57, 836-840 (1994).
28. Chirgwin KD, Feldman J, Augenbraun M et al. Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women. J. Infect. Dis. 172, 235-238 (1995).
29. Iwatsuki K, Tagami H, Takigawa M, Yamada M. Plane warts under spontaneous regression. Immunopathologic study on cellular constituents leading to the inflammatory reaction. Arch. Dermatol. 122, 655-659 (1986).
30. Apple,RJ Erlich, HA Klitz W et al. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat. Genet. 6, 157-162 (1994).
31. Odunsi K, Terry G, Ho L et al. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int. J. Cancer 67, 595-602 (1996).
32. Tsukui T, Hildesheim A, Schiffman MH et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res. 56, 3967-3974 (1996).
33. + cytotoxic T cells (CTLs) for cervical cancer precursor disease protection.
34. + CTLs for HPV-associated disease protection.
35. Sarkar AK, Tortolero-Luna G, Follen M, Sastry KJ. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV 16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecol. Oncol. 99, S251-S261 (2005). •• Direct correlation between cellular responses to E6 and E7 and recurrence-free survival in HPV patients treated for cervical intraepithelial neoplasia (CIN).
36. Kim TW, Hung CF, Boyd DA et al. Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res. 64, 400-405 (2004).
37. Kim TW, Hung CF, Kim JW et al. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum. Gene Ther. 15, 167-177 (2004).
38. Cheng WF, Hung CF, Hsu KF et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum. Gene Ther. 13, 553-568 (2002).
39. Hung CF, Cheng WF, Hsu KF et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res. 61, 3698-3703 (2001).
40. + T-cell responses that home to the tumor site. J. Virol.. 75, 9654-9664 (2001).
41. Liu DW, Tsao YP, Kung JT et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol.. 74, 2888-2894 (2000).
42. Ahn WS, Bae SM, Kim TY et al. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum. Gene Ther. 14, 1389-1399 (2003).
43. + CTLs in antitumor protective functions in an animal cervical cancer model.
44. Kim MS, Sin JI. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunol. 116, 255-266 (2005).
45. Fernando GJP, Murray B, Zhou J, Frazer IH. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin. Exp. Immunol. 115, 397-403 (1999).
46. Cui Z, Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol. Immunother. 54, 1180-1190 (2005).
47. Thompson HS, Davies ML, Holding FP et al. Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 17, 40-49 (1999).
48. de Jong A, O'Neill T, Khan AY et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20, 3456-3464 (2002).
49. Hallez S, Simon P, Maudoux F et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol. Immunother. 53, 642-650 (2004).
50. Greenfield I, Nickerson J, Penman S, Stanley M. Human papillomavirus 16 E7 protein is associated with the nuclear matrix. Proc. Natl. Acad. Sci. USA 88, 11217-11221 (1991).
51. Reinstein E, Scheffner M, Oren M, Ciechanover A, Schwartz A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 19, 5944-5950 (2000).
52. Kanda T, Zanma S, Watanabe S, Furuno A, Yoshiike K. Two immunodominant regions of the human papillomavirus type 16 E7 protein are masked in the nuclei of monkey COS-1 cells. Virology 182, 723-731 (1991).
53. Ji H, Wang TL, Chen CH et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum. Gene Ther. 10, 2727-2740 (1999).
54. Smahel M, Sima P, Ludvikova V, Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281, 231-238 (2001).
55. Higgins TJ, Herold KM, Arnold RL, McElhiney SP, Shroff KE, Pachuk CJ. Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses. J. Infect. Dis. 182, 1311-1320 (2000).
56. Strasser JE, Arnold RL, Pachuk C, Higgins TJ, Bernstein DI. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs. J. Infect. Dis. 182, 1311-1320 (2000).
57. Cheung YK, Cheng SC, Sin FW, Xie Y. Plasmid encoding papillomavirus type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Vaccine 23, 629-638 (2004).
58. Cheng WF, Hung CF, Chai CY et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. 108, 669-678 (2001).
59. Hung CF, He L, Juang J, Lin TJ, Ling M, Wu TC. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J. Virol. 76, 2676-2682 (2002).
60. Hung CF, Cheng WF, He L et al. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res. 63, 2393-2398 (2003).
61. Hsu KF, Hung CF, Cheng WF et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. 8, 376-383 (2001).
62. Suzue K, Young RA. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J. Immunol. 156, 873-879 (1996).
63. + CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule. Vaccine 17, 373-383 (1999).
64. Osen W, Peiler T, Ohlschlager P et al. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 19, 4276-4286 (2001).
65. Doan T, Herd K, Ramshaw I, Thomson S, Tindle RW. A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour. Cancer Immunol. Immunother. 54, 157-171 (2005).
66. Sin JI Kim JJ, Boyer JD, Higgins TJ, Ciccarelli RB, Weiner DB. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J. Virol. 73, 501-509 (1999).
67. + T cell mediated protective immunity against HSV-2challenge. J. Immunol. 162, 2912-2921 (1999).
68. Kim,TW, Hung CF, Ling M et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J. Clin. Invest. 112, 109-117 (2003).
69. Shedlock DJ, Weiner D.B. DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol. 68, 793-806 (2000).
70. Ray NB, Ewalt LC, Lodmell DL. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protects mice against lethal rabies virus infection. Vaccine 15, 892-895 (1997).
71. Wang B, Ugen KE, Srikantan V et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 90, 4156-4160 (1993).
72. Levy MY, Barron LG, Meyer KB, Szoka FC Jr. Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Ther.3, 201-211 (1996).
73. Lu S, Santoro JC, Fuller DH et al. Use of DNAs expressing HIV-1 env and noninfectious HIV particles to raise antibody responses in mice. Virology 209, 147-154 (1995).
74. Pertmer TM, Eisenbraun MD, McCabe D et al. Gene gun-based nucleic acid immunization; elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13, 1427-1430 (1995).
75. + T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector and syringe. Vaccine 21, 4036-4042 (2003).
76. Steinman R.M. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. 9, 271-296 (1991).
77. De Bruijn ML, Schuurhuis DH, Vierboom MP et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res.. 58, 724-731 (1998).
78. + T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res. 59, 1184-1187 (1999).
79. Kim TG, Kim CH, Won EH et al. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific anti-tumor immunity in a HPV 16 (E6/E7)-associated tumor animal model. Immunol. 112, 117-125 (2004).
80. Santin AD, Hermonat PL, Ravaggi A et al. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J. Virol.. 73, 5402-5410 (1999). • Immunogenicity studies of dendritic cell (DC)-based vaccines in three cervical cancer patients.
81. Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 166, 5917-5924 (2001).
82. Tillman BW, Hayes TL, DeGruijl TD et al. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res. 60, 5456-5463 (2000).
83. Chiriva-Internati M, Liu Y, Salati E et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur. J. Immunol. 32, 30-38 (2002).
84. Santin AD, Bellone S, Gokden M et al. Vaccination with HPV-8 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. New Engl. J. Med. 346, 1752-1753 (2002).
85. Ferrara A, Nonn M, Sehr P et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J. Cancer Res. Clin. Oncol. 129, 521-530 (2003). • Clinical trials of E7-primed DC vaccines in 15 cervical cancer patients: DCs were immunogenic but were not effective clinically.
86. Santin AD, Bellone S, Palmieri M et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol. Oncol. 100, 469-478 (2006).
87. He Z, Wlazlo AP, Kowalczyk DW et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV 16. Virology 270, 146-161 (2000).
88. Borysiewicz LK, Fiander A, Nimako M et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347, 1523-1527 (1996). • Immunogenicity studies of vaccinia viral vector delivery in patients with cervical cancer.
89. Kaufmann AM, Stern PL, Rankin EM et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-8 E6 and E7 genes, in women with progressive cervical cancer. Clin. Cancer Res. 8, 3676-3685 (2002). • Safety and immunogenicity studies in 29 subjects with stage Ib or IIa cervical cancer by vaccina viral vector delivery
90. Garcia-Hernandez E, Gonzalez-Sanchez JL, andrade-Manzano A et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther. 13, 592-597 (2006). • Clinical effectiveness of E2-targeted viral vectors for treating precusor cervical cancer disease.
91. Krul MR, Tijhaar EJ, Kleijne JA et al. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol. Immunother. 43, 44-48 (1996).
92. Di Fabio S, Medaglini D, Rush CM et al. Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. Vaccine 16, 485-492 (1998).
93. Gunn GR, Zubair A, Peters, C et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV 16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV 16. J. Immunol. 167, 6471-6479 (2001).
94. Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F et al. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J. Immunol. 175, 7297-7302 (2005).
95. Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242-2249 (1993).
96. Zwaveling S, Ferreira Mota SC, Nouta J et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358 (2002).
97. Cui Z, Qiu F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol. Immunother. 54, 1180-1190 (2005).
98. Muderspach L, Wilczynski S, Roman L et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res.. 6, 3406-3416 (2000). • Clinical effectiveness of peptide vaccines in treating precursor cervical cancer diseases.
99. van Driel WJ, Ressing ME, Kenter GG et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a Phase I-II trial. Eur. J. Cancer 35, 946-952 (1999). •• Peptide vaccines not clinically effective in advanced cervical cancer patients.
100. Kono K, Ressing ME, Brandt RM et al. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin. Cancer Res. 2, 1825-1828 (1996).
101. Ritz U, Momburg F, Pilch H et al.. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int. J. Oncol. 19, 1211-1220 (2001).
102. Bae SH, Park YJ, Park JB et al. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin. Cancer Res. 13(1)(2006) (In Press). •• Therapeutic synergy by chemotherapy plus E7 subunit vaccine-based immunotherapy in terms of tumor cure and recurrence rates, and long-term antitumor immunity.
103. Sin JI, Hong SH, Park YJ et al.. Antitumor therapeutic effects of E7 subunit and DNA vaccines in an animal cervical cancer model: antitumor efficacy of E7 therapeutic vaccines is dependent on tumor sizes, vaccine doses and vaccine delivery routes. DNA Cell Biol. 25, 277-286 (2006).
104. Baecher-Allan C, Anderson, DE. Regulatory cells and human cancer. Semin. Cancer Biol. 16, 98-105 (2006).
105. + regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 176, 1750-1758 (2006).
106. reg) cells in immunotherapy against cervical cancer in animals.
107. reg cells in immunotherapy against cervical cancer in humans.
108. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756-2761 (2002).
109. Wolf AM, Wolf D, Steurer M et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9, 606-612 (2003).